for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Finch Therapeutics Group Inc

FNCH.OQ

Latest Trade

13.96USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

11.56

 - 

22.50

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
13.96
Open
--
Volume
--
3M AVG Volume
1.13
Today's High
--
Today's Low
--
52 Week High
22.50
52 Week Low
11.56
Shares Out (MIL)
47.45
Market Cap (MIL)
673.30
Forward P/E
-7.43
Dividend (Yield %)
--

Latest Developments

More

Finch Therapeutics Reports Second Quarter 2021 Financial Results And Provides Business Update

Finch Therapeutics Group Inc Shares Open At $20.45 In Nasdaq Debut Versus IPO Price Of $17.00/Share

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Finch Therapeutics Group Inc

Finch Therapeutics Group, Inc. is a clinical-stage microbiome therapeutics company. The Company leveraging Human-First Discovery platform to develop a class of orally administered biological drugs. It is developing therapeutics designed to deliver missing microbes and their clinically relevant biochemical functions to correct dysbiosis and the diseases that emerge from it. The Company’s Human-First Discovery platform uses reverse translation to identify diseases of dysbiosis and to design microbiome therapeutics that address them. Its lead product candidate, CP101, delivers a complete microbiome and is being developed initially for the treatment of patients with recurrent Clostridioides difficile infection (CDI). It is also advancing CP101 for the treatment of chronic hepatitis B virus (HBV) Its product pipeline includes FIN-524, FIN-525, and FIN-211.

Industry

Business Services

Contact Info

200 Inner Belt Road

SOMERVILLE, MA

02143

United States

+1.617.2296499

https://finchtherapeutics.com/

Executive Leadership

Christopher W. Shumway

Independent Chairman of the Board

Mark Smith

President, Chief Executive Officer, Director

Andrew Noh

Co-Founder, Chief Administrative Officer

Gregory D. Perry

Chief Financial Officer

Marc Blaustein

Chief Operating Officer

Key Stats

1.33 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2020

0.0K

2021(E)

0.0K
EPS (USD)

2021(E)

-1.910
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
2.95
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up